Sumitomo Mitsui Trust Group Inc. Has $32.82 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Sumitomo Mitsui Trust Group Inc. trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 531,328 shares of the medical equipment provider's stock after selling 12,842 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.24% of Hologic worth $32,820,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. LaFleur & Godfrey LLC increased its position in Hologic by 2.9% during the fourth quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock worth $9,399,000 after buying an additional 3,655 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Hologic during the 4th quarter valued at about $4,215,000. Smartleaf Asset Management LLC raised its stake in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares in the last quarter. Schechter Investment Advisors LLC lifted its holdings in Hologic by 55.8% in the 4th quarter. Schechter Investment Advisors LLC now owns 5,494 shares of the medical equipment provider's stock worth $396,000 after purchasing an additional 1,968 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its position in Hologic by 5.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 25,398 shares of the medical equipment provider's stock worth $1,831,000 after purchasing an additional 1,338 shares during the period. 94.73% of the stock is owned by institutional investors.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus purchased 5,445 shares of the business's stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director directly owned 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.88% of the company's stock.

Hologic Price Performance

Shares of HOLX stock traded down $0.57 during mid-day trading on Thursday, reaching $64.74. The company's stock had a trading volume of 1,233,581 shares, compared to its average volume of 2,368,765. The firm's 50-day moving average is $60.45 and its two-hundred day moving average is $63.86. The company has a market cap of $14.43 billion, a P/E ratio of 27.31, a PEG ratio of 2.39 and a beta of 0.55. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company's quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.03 earnings per share. On average, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on HOLX. Royal Bank Of Canada dropped their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Raymond James Financial reissued an "outperform" rating and set a $71.00 target price (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Stephens lowered their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Finally, Morgan Stanley lowered their target price on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Twelve analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Hologic has an average rating of "Hold" and a consensus price target of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.